| Old Articles: <Older 6501-6510 Newer> |
 |
The Motley Fool July 29, 2010 Brian Orelli |
Forget Respect -- Dendreon Needs Sales! Dendreon's Provenge was approved months ago, but the data from the clinical trial supporting the FDA's decision was finally published in the New England Journal of Medicine this week.  |
The Motley Fool July 29, 2010 Brian Orelli |
This FDA Panel Isn't Brilliant Why does AstraZeneca's blood thinner Brilinta work better outside the U.S. than here at home? The Food and Drug Administration's advisory panel didn't seem to have a good explanation, but they didn't appear to care much, either.  |
The Motley Fool July 28, 2010 Brian Orelli |
Amplifying the Risk-Reward Ratio Amplify, Medtronic's latest, gets a mixed reaction at FDA advisory panel meeting.  |
The Motley Fool July 28, 2010 Brian Orelli |
Now There's an Illuminating Idea Helping your customers sell more of your product makes a lot of sense.  |
The Motley Fool July 28, 2010 Brian Orelli |
Fighting Hard to Keep a Blockbuster Sanofi is suing the FDA to take back approval of a competing generic drug. Did you expect something different?  |
The Motley Fool July 28, 2010 Jordan DiPietro |
3 Biotechs on Your Radar Screen It's not easy keeping track of all the drugs coming in and out of the development pipeline, but if you can stay up to date, you often have an advantage  |
The Motley Fool July 27, 2010 Tom Lydon |
Biotech ETFs Feeling the Winds of Change What's shaking up biotech as patents expire and M&A activity gathers steam?  |
InternetNews July 27, 2010 |
Oracle Debuts Drug-Tracking App for Big Pharma With its new Pedigree and Serialization Manager, Oracle is pitching an application to pharmaceutical companies that will enable them to track the movement of drugs across the supply chain.  |
InternetNews July 27, 2010 |
FDA, FCC Push For Wireless Health Technology The government agencies are teaming up to use the latest and greatest wireless technology to improve care and reduce healthcare costs using electronic health records.  |
The Motley Fool July 27, 2010 Jim Mueller |
3 Stocks to Play Biotech Here are three promising ideas for this exciting area.  |
| <Older 6501-6510 Newer> Return to current articles. |